Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 1309 | 206.79 |
09:34 ET | 200 | 208.39 |
09:36 ET | 400 | 208.47 |
09:43 ET | 169 | 209.68 |
09:50 ET | 542 | 208.535 |
09:52 ET | 100 | 208.515 |
09:56 ET | 200 | 208.485 |
09:57 ET | 239 | 208.59 |
10:01 ET | 100 | 208.19 |
10:03 ET | 267 | 209.82 |
10:08 ET | 100 | 209.98 |
10:10 ET | 574 | 208.5402 |
10:12 ET | 100 | 210.16 |
10:14 ET | 100 | 211.28 |
10:15 ET | 100 | 211.06 |
10:17 ET | 4380 | 211.62 |
10:21 ET | 100 | 211.96 |
10:24 ET | 100 | 210.94 |
10:26 ET | 100 | 210.565 |
10:28 ET | 200 | 210.8517 |
10:30 ET | 100 | 211.18 |
10:35 ET | 1360 | 211.37 |
10:37 ET | 100 | 211.71 |
10:39 ET | 300 | 211.37 |
10:42 ET | 496 | 212.035 |
10:46 ET | 300 | 212.565 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.5B | -8.3x | --- |
Biohaven Ltd | 4.6B | -5.4x | --- |
BridgeBio Pharma Inc | 4.7B | -9.5x | --- |
Immunovant Inc | 4.2B | -15.0x | --- |
Crinetics Pharmaceuticals Inc | 4.2B | -13.9x | --- |
Arcellx Inc | 4.4B | -76.4x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.44 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | 310.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.